These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38861400)

  • 41. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II.
    Gong Y; Li X; Ma X; Yu H; Li Y; Chen J; Zhang G; Wang B; Qi X; Meng H; Wang X; Mu J; Hu X; Wang J; Liu S; Liu G; Yang Z; Zhou Y; Kong X; Yan Y; Wang C; Wang JA; Wang L; Fu G; Wei L; Peng D; Zhang S; Li R; Mao A; Bian R; Tang W; Ran Y; Jiang J; Huo Y
    Clin Cardiol; 2021 Nov; 44(11):1575-1585. PubMed ID: 34651329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Gao Q; Palagashvilli T; Alam S; Mues KE; Bhatt DL; Kosiborod MN;
    JAMA Cardiol; 2021 Sep; 6(9):1060-1068. PubMed ID: 34132735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.
    Qureshi N; Antoniou S; Cornel JH; Schiele F; Perrone-Filardi P; Brachmann J; Sidelnikov E; Villa G; Ferguson S; Rowlands C; González-Juanatey JR
    Adv Ther; 2023 Jan; 40(1):233-251. PubMed ID: 36289145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study.
    Barrios V; Pintó X; Escobar C; Varona JF; Gámez JM
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
    Gavina C; Seabra-Carvalho D; Aguiar C; Anastassopoulou A; Teixeira C; Ruivo JA; Almeida É; Luz-Duarte L; Corte-Real A; Canelas-Pais M; Taveira-Gomes T
    Clin Cardiol; 2024 Jan; 47(1):e24183. PubMed ID: 37933175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea.
    Kim S; Han S; Rane PP; Qian Y; Zhao Z; Suh HS
    PLoS One; 2020; 15(1):e0228472. PubMed ID: 31999714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
    Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
    Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II.
    Yan BP; Chiang FT; Ambegaonkar B; Brudi P; Horack M; Lautsch D; Vyas A; Gitt AK
    Int J Cardiol; 2018 Aug; 265():1-5. PubMed ID: 29885676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.